News

10/10/2017

The 9th ADVANCE Forum/General Assembly Meeting

We are pleased to announce that the 9th ADVANCE Forum/General Assembly Meeting will be held on the 10th and 11th of October 2017 in Barcelona. 
21/08/2017

D5.6 Results of POC-phase 1 studies

The results described in this report are from the proof of concept studies conducted as part of the IMI ADVANCE project with the aim of testing the methodological aspects of the design, conduct and reporting of studies for vaccine benefit-risk...
01/08/2017

A paper from the WP1 has been published

The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations has been published.
30/06/2017

Article on Codemapper has been published

We are please to announce that the paper entitled CodeMapper: semiautomatic coding of case definitions. A contribution from the ADVANCE project has been published in Pharmacoepidemiology and Drug Safety journal. In this paper, the authors present...
02/06/2017

ICPE 2017, Montreal, Canada

ADVANCE will be represented at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management through two poster presentations and two oral presentations: - Methodology to estimate the health burden of adverse events...
31/05/2017

The WP4 White Paper has been submitted to IMI

We are pleased to inform you that the Deliverable D4.9 WP4 White Paper: methods for vaccine benefit-risk monitoring, including vaccine coverage, safety and effectiveness has been submitted to IMI on Wednesday 31st of...
17/05/2017

ADVANCE General Assembly and SAB Meeting

The ADVANCE 8th General Assembly and SAB Meeting will take place on May 17th and 18th in Sitges, Barcelona.
02/05/2017

Application of real-time global media monitoring and ‘derived questions’ for…

This article is published in the BMC Medicine journal. Read https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0850-4
02/05/2017

ADVANCE organised a workshop

ADVANCE organised a workshop at the European Medicines Agency on March 23-24th 2017 to discuss Public-private collaborations & partnerships for vaccine benefit-risk monitoring in Europe, attended by 63 participants from sectors such as...